Education
About Us
Working with TipRanks
Follow Us
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990)
:6990
6990 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$120.20 - HK$346.00
Previous CloseN/A
Volume210.00K
Average Volume (3M)694.01K
Market Cap
HK$70.04B
Enterprise ValueHK$34.01B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Sep 01, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding131,430,790
10 Day Avg. Volume656,241
30 Day Avg. Volume694,012
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$281.95Price Target Upside-5.58% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H News
PremiumCompany Announcements
Sichuan Kelun-Biotech Completes H Share Full Circulation
PremiumCompany Announcements
Sichuan Kelun-Biotech’s SKB518 Receives FDA Clearance for Clinical Trials
PremiumCompany Announcements
Sichuan Kelun-Biotech Gains Approval for H Share Circulation
PremiumCompany Announcements
Sichuan Kelun-Biotech Advances H Share Full Circulation Plan
PremiumCompany Announcements
Sichuan Kelun-Biotech Receives Approval for Novel Cancer Treatment Drug
PremiumCompany Announcements
Sichuan Kelun-Biotech Announces Board Changes and Governance Amendments
PremiumCompany Announcements
Sichuan Kelun-Biotech Reports Revenue Growth and Advances in Cancer Treatment---
Bulls Say, Bears Say
Bulls Say
CommercializationSignificant strides in commercialization with three commercialized assets and plans to expand the commercial team to 500+ employees by 2Q25.
Financial PerformanceKelun-Biotech reported strong financial results for 2024, driven by milestone payments from global collaborations and the progression of its innovative pipeline.
InnovationKelun-Biotech is advancing a multi-pronged ADC strategy across oncology and non-oncology, leveraging novel payloads, bispecific ADCs, and next-generation conjugation technologies.
Licensing DealKelun-Biotech and Harbour Biomed have successfully out-licensed global rights for their co-developed TSLP mAb SKB378 to Windward, valued at up to US$970 million plus royalties.
PartnershipsLicensing and collaboration agreements contributed RMB 1.86bn revenue, reflecting strong partnerships, particularly milestone payments from MSD.
Bears Say
Net LossThe Company narrowed its net loss significantly to RMB 266.8mn, an improvement from RMB 574.1mn in 2023, as revenue growth outpaced cost expansion.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.21%
Mutual Funds
― Other Institutional Investors
97.79% Public Companies and
Individual Investors
6990 FAQ
What was Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price range in the past 12 months?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H lowest stock price was HK$120.20 and its highest was HK$346.00 in the past 12 months.
What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s market cap?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s market cap is HK$70.04B.
When is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date is Sep 01, 2025 which is in 129 days.
How were Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s earnings last quarter?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H released its earnings results on Mar 24, 2025. The company reported -HK$2.582 earnings per share for the quarter, beating the consensus estimate of -HK$2.686 by HK$0.104.
Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H overvalued?
According to Wall Street analysts Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price is currently Overvalued.
Does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H pay dividends?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H does not currently pay dividends.
What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s EPS estimate?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s EPS estimate is -0.66.
How many shares outstanding does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H have?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has 131,430,790 shares outstanding.
What happened to Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H reported an EPS of -HK$2.582 in its last earnings report, beating expectations of -HK$2.686. Following the earnings report the stock price went up 0.231%.
Which hedge fund is a major shareholder of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6990
---
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$281.95 (-5.58% Downside)
HK$281.95 (-5.58% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.12%
12-Months-Change
Fundamentals
Return on Equity
-9.52%
Trailing 12-Months
Asset Growth
17.54%
Trailing 12-Months
6990 Stock 12 Month Forecast
Average Price Target
HK$281.95
▼(-5.58% Downside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
China Medical System Holdings
―
Shanghai Pharmaceuticals Holding Co
―
Best Analysts Covering 6990
1 Year
1 Year Success Rate
5/5 ratings generated profit
1 Year Average Return
+63.08%
reiterated a buy rating last month
Copying Jill Wu's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +63.08% per trade.
---